News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
NEWYORK, Dec. 7, 2022 – Hyfe, Inc., the global leader in AI-powered cough detection, tracking and classification, has been named by CB Insights to the 2022 Digital Health 150, a listing of the most promising companies transforming the future of health care with digital technology. More than 13,000 private companies were considered for the list.
Utilizing the CB Insights platform, the research team selected 150 winners based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength and tech novelty.
From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology. This increasingly global cohort, representing more than 18 countries across five continents, is not only driving better patient outcomes, but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.
Brian Lee
SVP of CB Insights’ Intelligence Unit
Vitals like blood pressure, temperature, pulse and respiration rate are measured to an exact number, yet persistent cough has never been measured with any accuracy. Studies show that when asked, patients have very limited ability to assess the frequency of their coughing or to detect significant changes in its patterns. Objective data helps people with cough have more productive conversations with their health care providers.
This recognition from CB Insights reinforces our commitment to improving the ability to recognize and treat cough and respiratory illness. Acoustic epidemiology, or the study of bodily sounds, combined with artificial intelligence adds a powerful layer of data for monitoring and screening patients that will provide clinical researchers with more accurate information and ultimately lead to better and more effective treatment.
Iulian Circo
Co-founder of Hyfe
CB Insights builds software that enables the world's best companies to discover, understand and make technology decisions with confidence. By marrying data, expert insights and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. More information is available at cbinsights.com.
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations that can greatly improve treatment and prevention.
With more than 380 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University, University of California at San Francisco and Queen’s University in Belfast. The company was founded in 2020 and is headquartered in Wilmington, Delaware.
More information is available at Hyfe.com, or on Hyfe's page on Linkedin.
# # #
Note to media: Images to accompany this story can be downloaded at https://hyfe.pressrep.net.
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.